ADC Therapeutics Share Price Today

ADC Therapeutics Q3FY26 Results: Adj. EPS beats estimate, sales up 32% YoY

Adjusted EPS of $(0.06) beat the $(0.21) consensus estimate by 71.43%. Quarterly sales rose 32.20% YoY to $21.716 million, beating estimates by 16.18%. Losses narrowed from $(0.19) per share in the same period last year. Company maintains expected cash runway into 2029 despite debt servicing risks.

Tanabe Pharma files Japan MAA for ZYNLONTA after positive trial data

Tanabe Pharma filed a Marketing Authorization Application for ZYNLONTA in Japan. Phase 2 study showed an overall response rate of 58.1% in Japanese patients. Complete response rate reached 41.9% with no new safety concerns identified. Exclusive sublicensing agreement signed with Nippon Shinyaku Co., Ltd.

ADC Therapeutics secures $86.6M PIPE to fund ZYNLONTA studies

ADC Therapeutics raised $86.6 million through a PIPE financing involving 12.9 million shares and 48.1 million pre-funded warrants. Outstanding term loan principal reduced to $50.0 million following a $70.0 million prepayment under amended Loan Agreement terms. Expected Q3FY26 net product revenues from ZYNLONTA are approximately $21.0 million, with proforma cash position reaching ~$196 million. Warrant exercise prices were significantly reduced, with HCR warrants dropping to $0.10 and Lender warrants to $1.00 per share.

ADC Therapeutics Q2 Results: Net Loss Falls 71% to $16.6 Million

ADC Therapeutics reported Q2 2026 results with a GAAP net loss of $16.6 million, significantly lower than the $56.6 million loss in Q2 2025. Net product revenue for Zynlonta rose slightly to $18.6 million. The company reduced its workforce by 17%, aiming for $10 million in annualized savings. Cash reserves stood at $219.1 million, supporting operations into 2028. Regulatory progress includes FDA concerns over LOTIS 5 but promising data from LOTIS 7.

ADC Therapeutics completes LOTIS-7 enrollment for ZYNLONTA

ADC Therapeutics SA completed enrollment in the LOTIS-7 Phase 1b trial evaluating ZYNLONTA plus glofitamab in 100 r/r DLBCL patients, with full data expected by the end of 2026. Concurrently, the company is reducing its workforce by 17% to save $10 million annually, extending its cash runway into 2028, while preparing for a pre-sBLA FDA meeting in August 2026.

Pomerantz investigates ADC Therapeutics over trial data

Pomerantz LLP investigates ADC Therapeutics SA for potential securities fraud following Phase 3 LOTIS-5 trial data showing higher deaths in the ZYNLONTA arm. The stock dropped 66.56% to $1.03 on June 5, 2026, after the announcement.